PMID- 37681826
OWN - NLM
STAT- MEDLINE
DCOM- 20230911
LR  - 20230912
IS  - 1660-4601 (Electronic)
IS  - 1661-7827 (Print)
IS  - 1660-4601 (Linking)
VI  - 20
IP  - 17
DP  - 2023 Aug 30
TI  - Maternal, Fetal and Neonatal Outcomes Related to Recreational Cannabis Use during 
      Pregnancy: Analysis of a Real-World Clinical Data Warehouse between 2010 and 
      2019.
LID - 10.3390/ijerph20176686 [doi]
LID - 6686
AB  - BACKGROUND: Cannabis is the main illicit psychoactive substance used in French 
      childbearing women and very few data are available about adverse events (AEs) 
      related to its use during pregnancy. The aim of this study was to evaluate the 
      association between recreational cannabis use during pregnancy and adverse 
      outcomes from a real-world clinical data warehouse. METHODS: Data from the 
      Poitiers University Hospital warehouse were analyzed between 1 January 2010 and 
      31 December 2019. Logistic regression models were used to evaluate associations 
      between outcomes in three prenatal user groups: cannabis alone +/- tobacco (C +/- T) 
      (n = 123), tobacco alone (T) (n = 191) and controls (CTRL) (n = 355). RESULTS: 
      Pregnant women in the C +/- T group were younger (mean age: 25.5 +/- 5.7 years), had 
      lower pre-pregnancy body mass index (22.8 +/- 5.5 kg/m(2)), more psychiatric 
      history (17.5%) and were more likely to benefit from universal free health-care 
      coverage (18.2%) than those in the T and CTRL groups. Cannabis use increases the 
      occurrence of voluntary interruption of pregnancy, at least one AE during 
      pregnancy, at least one neonatal AE, the composite adverse pregnancy outcome over 
      28, prematurity and small for gestational age. CONCLUSION: Given the 
      trivialization of recreational cannabis use during pregnancy, there is an urgent 
      need to communicate on AEs of cannabis use during pregnancy.
FAU - Bouquet, Emilie
AU  - Bouquet E
AD  - Addictovigilance Center, Department of Clinical Pharmacology, Poitiers University 
      Hospital, 86000 Poitiers, France.
AD  - French National Institute of Health and Medical Research (INSERM) U1084, 
      Experimental and Clinical Neurosciences Laboratory, University of Poitiers, CEDEX 
      9, 86073 Poitiers, France.
AD  - Clinical Investigation Center CIC1402, INSERM, Poitiers University Hospital, 
      University of Poitiers, 86000 Poitiers, France.
FAU - Blouin, Pascal
AU  - Blouin P
AD  - Department of Clinical Research and Innovation, Poitiers University Hospital, 
      86000 Poitiers, France.
FAU - Perault-Pochat, Marie-Christine
AU  - Perault-Pochat MC
AD  - Addictovigilance Center, Department of Clinical Pharmacology, Poitiers University 
      Hospital, 86000 Poitiers, France.
AD  - French National Institute of Health and Medical Research (INSERM) U1084, 
      Experimental and Clinical Neurosciences Laboratory, University of Poitiers, CEDEX 
      9, 86073 Poitiers, France.
AD  - Clinical Investigation Center CIC1402, INSERM, Poitiers University Hospital, 
      University of Poitiers, 86000 Poitiers, France.
FAU - Carlier-Guerin, Caroline
AU  - Carlier-Guerin C
AD  - Department of Obstetrics and Gynecology, Poitiers University Hospital, 86000 
      Poitiers, France.
FAU - Millot, Frederic
AU  - Millot F
AD  - Department of Pediatrics, Poitiers University Hospital, 86000 Poitiers, France.
FAU - Ricco, Jean-Baptiste
AU  - Ricco JB
AUID- ORCID: 0000-0003-1912-900X
AD  - Department of Clinical Research and Innovation, Poitiers University Hospital, 
      86000 Poitiers, France.
FAU - De Keizer, Joe
AU  - De Keizer J
AUID- ORCID: 0000-0003-0821-4540
AD  - Clinical Investigation Center CIC1402, INSERM, Poitiers University Hospital, 
      University of Poitiers, 86000 Poitiers, France.
FAU - Pain, Stephanie
AU  - Pain S
AUID- ORCID: 0000-0002-7499-0401
AD  - Addictovigilance Center, Department of Clinical Pharmacology, Poitiers University 
      Hospital, 86000 Poitiers, France.
AD  - French National Institute of Health and Medical Research (INSERM) U1084, 
      Experimental and Clinical Neurosciences Laboratory, University of Poitiers, CEDEX 
      9, 86073 Poitiers, France.
FAU - Guetarni, Farid
AU  - Guetarni F
AD  - Department of Clinical Research and Innovation, Poitiers University Hospital, 
      86000 Poitiers, France.
LA  - eng
PT  - Journal Article
DEP - 20230830
PL  - Switzerland
TA  - Int J Environ Res Public Health
JT  - International journal of environmental research and public health
JID - 101238455
RN  - 0 (Hallucinogens)
SB  - IM
MH  - Infant, Newborn
MH  - Female
MH  - Humans
MH  - Pregnancy
MH  - Young Adult
MH  - Adult
MH  - *Cannabis/adverse effects
MH  - Data Warehousing
MH  - *Hallucinogens
MH  - Body Mass Index
MH  - Health Facilities
PMC - PMC10487904
OTO - NOTNLM
OT  - adverse events
OT  - perinatal
OT  - pregnancy
OT  - recreational cannabis
COIS- The authors declare no conflict of interest.
EDAT- 2023/09/08 12:43
MHDA- 2023/09/11 06:43
PMCR- 2023/08/30
CRDT- 2023/09/08 08:54
PHST- 2023/06/30 00:00 [received]
PHST- 2023/08/28 00:00 [revised]
PHST- 2023/08/29 00:00 [accepted]
PHST- 2023/09/11 06:43 [medline]
PHST- 2023/09/08 12:43 [pubmed]
PHST- 2023/09/08 08:54 [entrez]
PHST- 2023/08/30 00:00 [pmc-release]
AID - ijerph20176686 [pii]
AID - ijerph-20-06686 [pii]
AID - 10.3390/ijerph20176686 [doi]
PST - epublish
SO  - Int J Environ Res Public Health. 2023 Aug 30;20(17):6686. doi: 
      10.3390/ijerph20176686.